A Phase Ib, Multi-center, Open-label Study to Evaluate the Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer Who Are Intolerant of or Who Have Progressed Despite Treatment With VEGF-targeted Therapies.
Phase of Trial: Phase I
Latest Information Update: 30 Jul 2014
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cancer
- Focus Adverse reactions
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 23 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Sep 2013 Planned end date changed from 1 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.